Navigation Links
TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
Date:11/12/2008

LA JOLLA, Calif., Nov. 12 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that the Board of Directors has appointed Evelyn Graham as the Company's Chief Executive Officer and as a member of the Company's Board of Directors. Ms. Graham had been serving as the Company's acting Chief Executive Officer since September 1, 2008.

"Ev has done an impressive job as acting CEO in managing the transition of our company and building a platform for the future," said Peter Davis, Chairman of the TorreyPines Board of Directors. "We are delighted that she has agreed to become CEO and a member of the Board at a time when TorreyPines is completing important clinical trials that hold promise for the company's future. With her considerable drug development experience as well as global senior management roles, she has the right mix of skills and experience to successfully lead the Company in meeting its strategic objectives."

"I am excited by this opportunity and look forward to continuing to work with TorreyPines' talented management team and dedicated employees," said Ms. Graham.

Ms. Graham joined TorreyPines in 2004 as Vice President, Development. She was then promoted to Vice President, Corporate Development in 2005, Chief Operating Officer in 2006 and acting Chief Executive Officer in September 2008. Prior to joining TorreyPines Ms. Graham was Executive Director, Development Operations at Purdue Pharma from 2000 to 2003. From 1998 to 2000, she was Senior Vice President of Business Development at Ingenix Pharmaceutical Services, a division of UHG, and served as Vice President of Clinical Operations at Worldwide Clinical Trials, prior to its acquisition by UHG. Previously, Ms. Graham held positions in oper
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
2. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
5. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
6. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
7. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
8. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
11. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Gain recognition for leadership and contribution ... biotech industry. Nominations are now being accepted for ... by the Bio Supply Management Alliance , ... professionals for the past 7 years. , Awards ... industry – Manufacturers, Service Providers, Material Suppliers, Technology ...
(Date:7/24/2014)... leader Yung-Eun Sung has announced that they have ... graphenes which can be applied as high performance ... Sung is both a group leader at the ... Science* (IBS) and a professor at the Seoul ... with regards to the development of relative simplicity, ...
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Genomics and Proteomics Analytical Instruments Market ... http://photos.prnewswire.com/prnh/20130307/600769 Genomics is the ... is the study of the structure and functions of ... and bioinformatics tools and technology. Genomics involves the mapping ...
(Date:7/24/2014)... July 24, 2014 2014 Deep ... Industry” is a professional and in-depth research report ... Potassium Sulphate basic information, including its definition, ... overview. This research covers the international market analysis, ... industry analysis covering macroeconomic environment & economic situation ...
Breaking Biology Technology:Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4
... ARBOR, Mich., Oct. 24 Gene Codes ... immediate,availability of the next version of Sequencher, ... analysis program. Researchers in academic labs ... which contains the essential genetic instructions key ...
... (OTC Bulletin Board: IMYN) CEO, Stephen Ferrone, will ... the Financial,Services Exchange (FSX) Investment Conference at the ... October 25, 2007. Immunosyn has obtained exclusive ... its largest shareholder, Argyll,Biotechnologies, LLC. Research suggests that ...
... Environment Where Scientists Thrive and Science is ... ... year, Abbott (NYSE: ABT ) has been named among the top ... Science is at the center of Abbott,s broad base of businesses. To,enhance ...
Cached Biology Technology:Gene Codes Corporation Announces Version 4.8 of Sequencher Software for DNA Sequence Assembly & Analysis 2Immunosyn Corporation to Present at FSX 2Abbott Named to Science Magazine's List of 'Top Employers' in the Biotech and Pharmaceutical Industry 2Abbott Named to Science Magazine's List of 'Top Employers' in the Biotech and Pharmaceutical Industry 3
(Date:7/25/2014)... the Terra satellite show the different areas that have been ... The burn scars show up as reddish-brown splotches of ... across the remote parts of Eastern Russia in the Sakha ... instrument, it is still possible to see the smoke ... noted below show the devastating number of fires that have ...
(Date:7/25/2014)... biomedical engineering at the University of Houston, has ... artificial organ development., "Introduction to Tissue Engineering: Applications ... into the field of artificial organ development. Metin ... at UH, served as a series editor on ... other published books on the subject of growing ...
(Date:7/25/2014)... of diffusion tensor tractography (DTT), which is derived ... estimation for three motor tracts, such as the ... pathway became possible. The corticospinal tract is known ... function in the human brain. Several studies have ... transtentorial herniation. In addition, some studies have demonstrated ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2
... Omnicell, Inc . (NASDAQ: OMCL ), a ... analytics software for healthcare facilities, today announced that ... supply and medication management solutions with the new fourth ... decade as an Omnicell pharmacy and supply automation customer, ...
... The cerebellum is far more intensively involved in helping ... effectively in spatial environments our brain, and particularly our ... cerebellum contributes to the creation of this map through ... ability is inactivated, the brain is no longer able ...
... available in Chinese on EurekAlert! Chinese . ... have published new research that improves the survival and effectiveness ... Chang Chan, from the Chinese University of Hong Kong, is ... has led to a variety of breakthroughs as stem cell ...
Cached Biology News:Athens Regional Medical Center Upgrades to Omnicell G4 Platform for Supply and Medication Management 2Athens Regional Medical Center Upgrades to Omnicell G4 Platform for Supply and Medication Management 3Athens Regional Medical Center Upgrades to Omnicell G4 Platform for Supply and Medication Management 4The cerebellum as navigation assistant 2Reprogramming stem cells to a more basic form results in more effective transplant, study shows 2
... Reagent A - Fixation medium Reagent ... are intended for fixing cells in suspension ... cells with Reagent B. This procedure gives ... the morphological scatter characteristics of the cells ...
... Intended Use: Vision Mount is formulated for covering ... alcohol soluble OR alcohol insoluble end products. , ... ... with chromogens such as Fast-Red or AEC that require an ...
... Solution, High pH This pH 9.9 ... prior to immunohistochemical staining procedures. It is ... mounted on glass slides. For particular antigens, ... especially effective. It should be noted that ...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
Biology Products: